Frontiers in neurology · 2025
Levodopa/carbidopa/entacapone versus levodopa/benserazide plus pramipexole in Chinese patients with Parkinson's disease experiencing wearing off.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Cuiyu, Liu Weiguo, Gong Aiping, Ye Min, Huang Hui, Zhao Yang, Liu Chunfeng, Guo Yijing, Chen Juping, Zhang Xueling, Chen Xianwen, Shen Lihua, Li Dan
Аннотация
OBJECTIVE: To compare the efficacy and safety of direct switch from levodopa/benserazide (LB) to levodopa/carbidopa/entacapone (LCE) versus LB plus pramipexole (PPX) in Chinese patients with Parkinson's disease (PD) experiencing wearing off (WO).
METHODS: In this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.
RESULTS: Seventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients' daily OFF time significantly after 8 weeks (-1.76 ± 1.70 h, p < 0.001 and -1.51 ± 1.60, p < 0.001, respectively), and the shortenings were comparable between the two groups (p = 0.414). Correspondingly, both the LCE group and the PPX group had significantly increased daily ON time (1.62 ± 1.59 h, p < 0.001 and 1.38 ± 1.65, p < 0.001, respectively), and the increases were comparable between the two groups (p = 0.412). Both treatments improved the patients' WO symptoms, sleep quality, depression and quality of life. Six (7.59%) patients in the LCE group and 7 (14.29%) patients in the PPX group reported TEAEs, all of which were mild and tolerable. One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia.
CONCLUSION: LCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO.
METHODS: In this multicenter, prospective, randomized, open-label, observational study, 140 patients with PD experiencing WO who had been on stable LB treatment were enrolled and randomized 3:2 to receive LCE (84) or LB + PPX (56) treatment for 8 weeks. The primary endpoint was change in the daily "OFF" time from baseline. Change in the daily "ON" time was also assessed. Treatment-emergent adverse events (TEAEs) were recorded.
RESULTS: Seventy-nine patients in the LCE group and 49 patients in the PPX group completed the study. Both LCE and PPX shortened the patients' daily OFF time significantly after 8 weeks (-1.76 ± 1.70 h, p < 0.001 and -1.51 ± 1.60, p < 0.001, respectively), and the shortenings were comparable between the two groups (p = 0.414). Correspondingly, both the LCE group and the PPX group had significantly increased daily ON time (1.62 ± 1.59 h, p < 0.001 and 1.38 ± 1.65, p < 0.001, respectively), and the increases were comparable between the two groups (p = 0.412). Both treatments improved the patients' WO symptoms, sleep quality, depression and quality of life. Six (7.59%) patients in the LCE group and 7 (14.29%) patients in the PPX group reported TEAEs, all of which were mild and tolerable. One patient in the LCE group and 2 patients in the PPX group experienced mild dyskinesia.
CONCLUSION: LCE and LB + PPX were both effective, safe and tolerable in treating patients with PD who experienced WO.